$-0.35 EPS Expected for PTC Therapeutics, Inc. (PTCT); Orrstown Financial Services (ORRF)’s Sentiment Is 1.61

April 23, 2018 - By Winifred Garcia

PTC Therapeutics, Inc. (NASDAQ:PTCT) Logo

Orrstown Financial Services Inc (ORRF) investors sentiment decreased to 1.61 in Q4 2017. It’s down -0.84, from 2.45 in 2017Q3. The ratio is negative, as 29 funds increased and opened new stock positions, while 18 sold and trimmed holdings in Orrstown Financial Services Inc. The funds in our database now hold: 3.35 million shares, up from 3.30 million shares in 2017Q3. Also, the number of funds holding Orrstown Financial Services Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 16 Increased: 22 New Position: 7.

Analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to report $-0.35 EPS on May, 14.They anticipate $0.50 EPS change or 58.82% from last quarter’s $-0.85 EPS. After having $0.03 EPS previously, PTC Therapeutics, Inc.’s analysts see -1,266.67% EPS growth. The stock decreased 1.72% or $0.45 during the last trading session, reaching $25.78. About 317,718 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 274.65% since April 23, 2017 and is uptrending. It has outperformed by 263.10% the S&P500.

Orrstown Financial Services, Inc. operates as the bank holding firm for Orrstown Bank that provides commercial banking and trust services in the United States. The company has market cap of $216.70 million. The firm accepts various deposits, including checking, savings, time, demand, and money market deposits. It has a 26.29 P/E ratio. The Company’s loan products include commercial loans, including commercial real estate, equipment, working capital, and other commercial purpose loans; consumer loans, such as home equity loans, home equity lines of credit, and other consumer loans; residential mortgage loans; and agribusiness, acquisition and development, municipal, and installment and other loans.

Endeavour Capital Advisors Inc holds 2.03% of its portfolio in Orrstown Financial Services, Inc. for 198,183 shares. Elizabeth Park Capital Advisors Ltd. owns 185,515 shares or 1.51% of their US portfolio. Moreover, Basswood Capital Management L.L.C. has 0.62% invested in the company for 526,900 shares. The Oregon-based Pacific Ridge Capital Partners Llc has invested 0.62% in the stock. Deprince Race & Zollo Inc, a Florida-based fund reported 298,333 shares.

Analysts await Orrstown Financial Services, Inc. (NASDAQ:ORRF) to report earnings on April, 26. They expect $0.30 EPS, up 25.00% or $0.06 from last year’s $0.24 per share. ORRF’s profit will be $2.52 million for 21.47 P/E if the $0.30 EPS becomes a reality. After $0.32 actual EPS reported by Orrstown Financial Services, Inc. for the previous quarter, Wall Street now forecasts -6.25% negative EPS growth.

Since January 1, 0001, it had 1 insider buy, and 0 selling transactions for $2,517 activity.

The stock increased 1.54% or $0.3913 during the last trading session, reaching $25.7613. About 21,702 shares traded or 67.00% up from the average. Orrstown Financial Services, Inc. (ORRF) has risen 15.42% since April 23, 2017 and is uptrending. It has outperformed by 3.87% the S&P500.

Since January 3, 2018, it had 0 insider buys, and 4 insider sales for $61,523 activity. $1,361 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) was sold by Almstead Neil Gregory. Peltz Stuart Walter sold $40,207 worth of stock or 2,230 shares. Shares for $7,280 were sold by Utter Christine Marie on Wednesday, January 3.

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. PTC Therapeutics had 40 analyst reports since July 31, 2015 according to SRatingsIntel. On Wednesday, July 5 the stock rating was maintained by RBC Capital Markets with “Hold”. Oppenheimer maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) rating on Thursday, February 25. Oppenheimer has “Outperform” rating and $111 target. Jefferies upgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) rating on Wednesday, February 24. Jefferies has “Hold” rating and $12 target. The rating was upgraded by JP Morgan to “Neutral” on Thursday, November 16. The company was downgraded on Tuesday, February 23 by JP Morgan. RBC Capital Markets maintained it with “Hold” rating and $31.0 target in Wednesday, March 7 report. On Friday, June 30 the stock rating was maintained by Cowen & Co with “Hold”. The rating was downgraded by Citigroup to “Neutral” on Wednesday, February 24. Citigroup maintained the shares of PTCT in report on Thursday, February 22 with “Buy” rating. Credit Suisse upgraded the stock to “Outperform” rating in Monday, November 14 report.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $1.20 billion. The company's lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

Investors sentiment decreased to 0.98 in 2017 Q4. Its down 0.73, from 1.71 in 2017Q3. It dived, as 23 investors sold PTC Therapeutics, Inc. shares while 35 reduced holdings. 23 funds opened positions while 34 raised stakes. 35.45 million shares or 7.80% more from 32.89 million shares in 2017Q3 were reported. New York State Common Retirement Fund reported 41,800 shares. Parametric Port Limited Com holds 27,120 shares or 0% of its portfolio. American Group has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). J Goldman & Limited Partnership holds 0.59% or 653,284 shares in its portfolio. Amer Century, a Missouri-based fund reported 191,441 shares. Goldman Sachs Grp stated it has 796,518 shares. Parallax Volatility Advisers Lp, a California-based fund reported 633,384 shares. Gp One Trading L P owns 569,373 shares or 0.07% of their US portfolio. Citadel Advsr Ltd Liability reported 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Manufacturers Life Insurance The owns 30,908 shares. Bnp Paribas Arbitrage Sa holds 8,458 shares or 0% of its portfolio. Eventide Asset Ltd Liability Co invested 0.06% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Axa invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Matarin Mgmt Ltd Limited Liability Company accumulated 16,587 shares. Kerrisdale Advisers Ltd Co owns 1.18% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 35,000 shares.

Orrstown Financial Services, Inc. (NASDAQ:ORRF) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: